Recommended Reading Materials

Although the lecture notes represent the only required reading material for this course, time constraints prohibit a comprehensive coverage of all essential topics in gastroenterology. You are therefore highly encouraged to supplement your reading during the course by the following two resources:

1. **Robbins Pathological Basis of Diseases**, 6th ed., 1998, W. B. Saunders Co. (Countway Course Reserve)
Chapter 18: The Gastrointestinal Tract
Chapter 19: Liver and the Biliary Tract
Chapter 20: The Pancreas

2. **Gastroenterology, Saunders Text and Review Series**, 1997, W. B. Saunders Co. (Countway Course Reserve).

Both of the above resources are well-written and concise, and include high-quality photographs and radiographs of classical gastrointestinal diseases. In addition to the above basic reading material, you may want to browse the following comprehensive texts and keep them in mind for future reference:

Histology and Pathology:

1. Chandrasoma, P. (1999). Gastrointestinal pathology. Stamford, Conn., Appleton & Lange.
2. Fawcett, D. W., W. Bloom, et al. (1997). A textbook of histology. New York, Chapman & Hall.
3. Fenoglio-Preiser, C. M. (1999). Gastrointestinal pathology: an atlas and text. Philadelphia, Lippincott-Raven.
4. Ming, S.-C. and H. Goldman (1998). Pathology of the gastrointestinal tract. Baltimore, Williams & Wilkins.
5. MacSween, R. N. M. (2001). Pathology of the liver. Edinburgh, New York, Churchill Livingstone.

Clinical Gastroenterology and Hepatology:

1. Gore, R. M. and M. S. Levine (2000). Textbook of gastrointestinal radiography. Philadelphia, W.B. Saunders.
2. Schiff, E. R., M. F. Sorrell, et al. (1998). Schiff's diseases of the liver. Philadelphia, Lippincott-Raven Publishers.
3. Sherlock, S. and J. Dooley (2001). Diseases of the liver and biliary system. Oxford, Malden, Mass., Blackwell Science.
4. Feldman, M., B. Scharschmidt, et al. (2002). Sleisenger & Fordtran's gastrointestinal and liver disease: pathophysiology, diagnosis, management. (7th ed.) Philadelphia, Pa., Saunders.
5. Tahara, E. (1997). Molecular pathology of gastroenterological cancer: application to clinical practice. Tokyo ; New York, Springer.
6. Zakim, D., Boyer T. (2002). Hepatology: A Textbook of Liver Disease (4th ed.) Philadelphia, W. B. Saunders.

Bibliography

1. Kerneis, S., *et al.* Molecular studies of the intestinal mucosal barrier physiopathology using cocultures of epithelial and immune cells: a technical update. *Microbes Infect* 2000. 2(9): 1119-24.
2. Blijlevens, N.M., J.P. Donnelly, and B.E. De Pauw. Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview. *Bone Marrow Transplant* 2000. 25(12): 1269-78.
3. Nervi, F. Significance of biliary phospholipids for maintenance of the gastrointestinal mucosal barrier and hepatocellular integrity [editorial]. *Gastroenterology* 2000.118(6): 1265-7.

4. Ouellette, A.J. IV. Paneth cell antimicrobial peptides and the biology of the mucosal barrier. *Am* J *Physiol* 1999. 277(2 Pt 1): G257-61. .

5. Perdue, M.H. Mucosal immunity and inflammation. III. The mucosal antigen barrier: cross talk with mucosal cytokines. *Am J Physiol 1999.* 277(1 Pt 1): GI-5.

6. DeWitt, R.C. and K.A. Kudsk. The gut's role in metabolism, mucosal barrier function, and gut immunology. *Infect Dis Clin North Am* 1999. 13(2): 465-81, x.

7. Diebel, L.N., *et al.* Synergistic. effect of hyperoxia and Unmunoglobulin A on mucosal barrier defense. J *Trauma* 1999.46(3): 374-8; discussion 378-9.

8. M. Rescigno, M. Urbano, B. Valzasina, M. Francolini, G. Rotta, R. Bonasio, F. Granucci, J.P. Kraehenbuhl and P. Ricciardi-Castagnoli , Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. *Nat Immunol* 2001; 2: 361-367

9. Turner, J.R. 'Putting the squeeze' on the tight junction: understanding cytoskeletal regulation. *Semin Cell Dev Bioi* 2000. 11(4): 301-8.

10. Mitic, L.L., C.M. Van Itallie, and J.M. Anderson. Molecular physiology and pathophysiology of tight junctions I. Tight junction structure and function: lessons from mutant animals and proteins. *Am* J *Physiol Gastrointest Liver Physiol* 2000. 279(2): G250-4.

11. Nusrat, A., *et al.* The coiled-coil domain of occludin can act to organize structural and functional elements of the epithelial tight junction. J *Bioi Chem* 2000. 275(38): 29816-22.

12. Bazzoni, G., *et al.* Interaction of junctional adhesion molecule with the tight junction components ZO-1, cingulin, and occludin. J *Biol Chem* 2000. 275(27): 20520-6.

13. Hopkins, AM., *et al.* Modulation of tight junction function by G protein-coupled events. *Adv Drug Deliv Rev* 2000. 41(3): 329-40. .

14. Clarke, H., *et al.* Modification of tight junction function by protein kinase C isoforms. *Adv Drug Deliv Rev* 2000.41(3): 283-301.

15. Walsh, S.V., A.M. Hopkins, and A. Nusrat. Modulation of tight junction structure and function by cytokines. *Adv Drug Deliv Rev* 2000. 41(3): 303-13.

16. Lapierre, L.A. The molecular structure of the tight junction. *Adv Drug Deliv Rev* 2000. 41(3): 255-64.

17. Tsukita, S. and M. Furuse. Pores in the wall: claudins constitute tight junction strands containing aqueous pores. J *Cell Biol* 2000. 149(1): 13-6.

18. Fujita, H., *et al.* Molecular deciphennent of Rho effector pathways regulating tight-junction penneability. *Biochem J 2000.* 346 Pt 3: 617-22.

19. T. Kinugasa, T. Sakaguchi, X. Gu and H.C. Reinecker , Claudins regulate the intestinal barrier in response to immune mediators. *Gastroenterology* 2000; 118: 1001-1011.

20. Sabri, S., *et al.* Glycocalyx modulation is a physiological means of regulating cell adhesion. *J Cell Sci* 2000. 113(Pt 9): 1589-600.

21. Kovbasnjuk, O.N. and K.R. Spring. The apical membrane glycocalyx of MDCK cells. J *Membr Biol* 2000. 176(1): 19-29.

22. Gebhard, A and A. Gebert. Brush cells of the mouse intestine possess a specialized glycocalyx as revealed by quantitative lectin histochemistry. Further evidence for a sensory function. *J Histochem Cytochem* 1999. 47(6): 799-808.

23. Mantis, N.J., A. Frey, and M.R. Neutra. Accessibility of glycolipid and oligosaccharide epitopes on rabbit villus and follicle-associated epithelium. *Am J Physiol Gastrointest Liver Physiol 2000.* 278(6): G915-23.

24. Sierro, F., *et al.* Transient expression of M-cell phenotype by enterocyte-like cells of the follicle-associated epithelium of mouse Peyer's patches. *Gastroenterology* 2000. 119(3): 734-43.

25. Meynell, H.M., *et al.* Up-regulation of microsphere transport across the follicle-associated epithelium of Peyer's patch by exposure to Streptococcus pneumoniae R36a. *FASEB* J 1999. 13(6): 611-9.

26. Debard, N., F. Sierro, and J.P. Kraehenbuhl. Development ofPeyer's patches, follicle-associated epithelium and M cell: lessons from immunodeficient and knockout mice. *Semin Immunol1999.* 11(3): 183-91.

27. Yamamoto, M., *et al.* Alternate mucosal immune system: organized Peyer's patches are not required

for IgA responses in the gastrointestinal tract *J Immunol2000.* 164(10): 5184-91.

28. Laky, K., *et 01.* Enterocyte expression of interleukin 7 induces development of gammadelta T cells and Peyer's patches. *J Exp Med* 2000. 191(9): 1569-80.

29. Iwasaki, A. and B.L. Kelsall. Localization of distinct Peyer's patch dendritic cell subsets and their recruitment by chemokines macrophage inflammatory protein (MIP)-3alpba, MIP-3beta, and secondary lymphoid organ chemokine. *J Exp Med* 2000. 191(8): 1381-94.

30. Warnock, RA., *et 01.* The role of chemokines in the microenvironmental control of T versus B cell arrest in Peyer's patch high endothelial venules. *J Exp Med* 2000. 191(1): 77-88.

31. Hathaway, LJ. and J.P. Kraehenbuhl. The role of M cells in mucosal immunity. *Cell Mol Life Sci* 2000. 57(2): 323-32.

32. Fujimura, Y. Evidence of M cells as portals of entry for antigens in the nasopharyngeal lymphoid tissue of humans. *Virchows Arch* 2000.436(6): 560-6.

33. Lelouard, H., *et 01.* Mucin-related epitopes distinguish M cells and enterocytes in rabbit appendix and Peyer's patches. *Infect Immun* 1999.67(1): 357-67.

34. Neutra, M.R M cells in antigen sampling in mucosal tissues. *Curr Top Microbiol Immunol* 1999. 236: 17-32.

35. Neutra, M.R. Interactions of viruses and microparticles with apical plasma membranes of M cells: implications for human immunodeficiency virus transmission. *J Infect Dis* 1999. 179 Suppl 3: S441-3.

36. Owen, RL. Uptake and transport of intestinal macromolecules and microorganisms by M cells in Peyer's patches-a personal and historical perspective. *Semin Immunol* 1999. 11(3): 157-63.

37. Sansonetti, p.J. and A. Phalipon. M cells as ports of entry for enteroinvasive pathogens: mechanisms of interaction, consequences for the disease process. *Semin Immunol1999.* 11 (3): 193-203.

38. Borghesi, C., M.J. Taussig, and C. Nicoletti. Rapid appearance of M cells after microbial challenge is restricted at the periphery of the follicle-associated epithelium of Peyer's patch. *Lab Invest* 1999. 79(11): 1393-401.

39. Janin, N. A simple model for carcinogenesis of colorectal cancers with microsatellite instability. *Adv Cancer Res* 2000. 77: 189-221. .

40. Crew, T.E., DJ. Elder, and C. Paraskeva. A cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug enhances the growth inhibitory effect of butyrate in colorectal carcinoma celli expressing COX-2 protein: regulation of COX-2 by butyrate. *Carcinogenesis* 2000. 21(1): 69-77.

41. Park, W.S., *et 01.* A distinct tumor suppressor gene locus on chromosome 15q21.1 in sporadic form of colorectal cancer. *Cancer Res* 2000.60(1): 70-3. .

42. Chapple, K.S., *et al.* Localization of cyc1ooxygenase-2 in human sporadic colorectal adenomas. *Am J Pathol* 2000.156(2): 545-53.

43. Brabletz, T., *et al.* Expression ofnuc1ear beta-catenin and c-myc is correlated with tumor size but not with proliferative activity of colorectal adenomas. *Am J Patho12000.* 156(3): 865-70.

44. Roncucci, L., *et al.* Aberrant crypt foci in colorectal carcinogenesis. Cell and crypt dynamics. *Cell Prolif* 2000.33(1): 1-18.

45. O'Brien, H., *et al.* K-ras mutations, rectal crypt cells proliferation, and meat consumption in patients with left-sided colorectal carcinoma. *Eur J Cancer Prev* 2000. 9(1): 41-7.

46. Wang, M.H., A.L. Kurtz, and Y. Chen. Identification of a novel splicing product of the RON receptor tyrosine kinase in human colorectal carcinoma cells. *Carcinogenesis* 2000. 21(8): 1507-12.

47. Tomlinson, 1. Different pathways of colorectal carcinogenesis and their clinical pictures. *Ann N Y Acad*

Sci 2000.910: 10-8; discussion 18-20.

48. Boland, C.R Molecular genetics of hereditary nonpolyposis colorectal cancer. *Ann NY Acad Sci* 2000.910: 50-9; discussion 59-61.

49. Giardina, C., H. Boulares, and M.S. Inan. NSAIDs and butyrate sensitize a human colorectal cancer cell line to TNF-alpha and Fas ligation: the role of reactive oxygen species. *Biochim Biophys Acta* 1999. 1448(3): 425-38.

50. Sakuma, K., *et 01.* Cyclooxygenase (COX)-2 immunoreactivity and relationship to p53 and Ki-67 expression in colorectal cancer. *J Gastroenterol 1999.* 34(2): 189-94. .

51. Abdel-Rahman, W.M., *et al.* Role of BAX mutations in mismatch repair-deficient colorectal carcinogenesis. *Oncogene* 1999. 18(12): 2139-42.

52. Breivik, J. and G. Gaudemack. Genomic instability, DNA methylation, and natural selection in colorectal carcinogenesis. *Semin Cancer Bioi* 1999. 9(4): 245-54.

53. Dyas, M., *et al.* Genetic pathways in colorectal and other cancers. *Eur J Cancer* 1999. 35(3): 335-51.

54. Yan, P., *et al.* Telomerase activation in colorectal carcinogenesis. *J Patho11999.* 189(2): 207-12.

55. Dannenberg, A.J. and D. Zakim. Chemoprevention of colorectal cancer through inhibition of cyclooxygenase-2. *Semin Onco11999.* 26(5): 499-504.

56. Liu, T., *et al.* Missense mutations in hMLH1 associated with colorectal cancer. *Hum Genet* 1999.105(5): 437-41.

57. Valentini, A.M., *et al.* Programmed cell death in colorectal carcinogenesis. *Anticancer Res* 1999. 19(4B): 3019-24.

58. Jiricny, J. and M. Nystrom-Lahti. Mismatch repair defects in cancer. *Curr Opin Genet Dev* 2000. 10(2): 15761.

59. Karnes, W.E., Jr. Implications oflow COX-2 expression in colorectal neoplasms with defective DNA mismatch repair. *J Cell Biochem* 2000. 77(S34): 23-27.

60. Johannsdottir, J. T., *et al.* The effect of mismatch repair deficiency on tumourigenesis; microsatellite instability affecting genes containing short repeated sequences. *Int J Onco12000.* 16(1): 133-9.

61. Lipkin, S.M., *et al.* MLH3: a DNA mismatch repair gene associated with mammalian microsateUite instability. *Nat Genet* 2000. 24(1): 27-35.

62. lino, H., *et al.* DNA microsatellite instability and mismatch repair protein loss in adenomas presenting in hereditary non-polyposis colorectal cancer. *Gut* 2000.47(1): 37-42.

63. Morteau, 0., *et al.* Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-l or cyclooxygenase-2. *J Clin Invest* 2000.105(4): 469-78.

64. Slomiany, B.L. and A. Slomiany. Induction of endothelin-converting enzyme-1 in gastric mucosal injury by idomethacin. *Biochem Biophys Res Commun* 2000. 269(2): 377-81.

65. Kelly, D., *et al.* Endothelial changes precede mucosal ulceration induced by indomethacin: an experimental study in the rat *Aliment Phannacol Ther* 2000.14(4): 489-96.

66. Takahashi, N., *et al.* Importance of gap junction in gastric mucosal restitution nom acid-induced injury. *J Lab Clin Med* 2000. 136(2): 93-9.

67. Vazquez, I., *et al.* Protective effect of enriched diet plus growth hormone administration on radiation-induced intestinal injury and on its evolutionary pattern in the rat *Dig Dis Sci* 1999.44(11): 2350-8.

68. Mylonas, P.G., *et al.* Growth hormone and insulin-like growth factor I protect intestinal cells nom radiation induced apoptosis. *Mol Cell Endocrinol 2000.* 160(1-2): 115-22.

69. Whittle, B.J. Pharmacological approach to the prevention of non-steroidal anti-inflammatory drug-induced gastropathy. *Ital J Gastroenterol Hepatol1999.* 31 (Suppl 1): S43-7.

70. Dumenil, G., P. Sansonetti, and G. Tran Van Nhieu. Src tyrosine kinase activity down-regulates Rho-dependent responses during Shigella entry into epithelial cells and stress fibre formation. *J Cell Sci* 2000. 113(Pt 1): 71-80.

71. Wenneras, C., *et al.* Blockade ofCD14 increases Shigella-mediated invasion and tissue destruction. *J Immunol2000.* 164(6): 3214-21.

72. Bourdet-Sicard, R., *et al.* Diversion of cytoskeletal processes by Shigella during invasion of epithelial cells. *Microbes Infect* 2000.2(7): 813-9.

73. Philpott, D.J., *et al.* Invasive Shigella flexneri activates NF-kappa B through a: lipopolysaccharide-dependent innate intracellular response and leads to IL-8 expression in epithelial cells. *J Immunol2000.* 165(2): 903-14.

74. Mimuro, H., *et al.* Profilin is required for sustaining efficient intra- and intercellular spreading of shigella flexneri *J Bioi Chem* 2000. 275(37): 28893-901.

75. Sansonetti, P.I., *et al.* Caspase-1 activation of lL-1beta and IL-18 are essential for Shigella flexneri-induced inflammation. *Immunity* 2000. 12(5): 581-90.

76. Suzuki, T., *et al.* Rho family GTPase Cdc42 is essential for the actin-based motility of Shigella in mammalian cells. *J Exp Med* 2000. 191(11): 1905-20.

77. Vimal, D.B., *et al.* Intestinal mucins: the binding sites for Salmonella typhimurium. *Mol Cell Biochem* 2000. 204(1-2): 107-17.

78. Gewirtz, A.T., *et al.* Salmonella typhimurium induces epithelial lL-8 expression via Ca(2+)-mediated activation of the NF-kappaB pathway. *J Clin Invest* 2000.105(1): 79-92.

79. Murray, RA. and C.A. Lee. Invasion genes are not required for Salmonella enterica serovar typhimurium To breach the intestinal epithelium: evidence that salmonella pathogenicity island 1 has alternative functions during infection. *Infect Immun* 2000. 68(9): 5050-5.

80. Wallis, T.S. and E.E. Galyov. Molecular basis of Salmonella-induced enteritis. *Mol Microbiol 2000.* 36(5): 997-1005.

81. Zhang, x.L., *et al.* Salmonella enteric a serovar typhi uses type IVB pili to enter human intestinal epithelial cells. *Infect Immun* 2000. 68(6): 3067-73.

82. Kingsley, R.A., *et al.* The shdA gene is restricted to serotypes of Salmonella enteric a subspecies I and contributes to efficient and prolonged fecal shedding. *Inftct Immun* 2000. 68(5): 2720-7.

83. Bao, S., *et al.* Interferon-gamma plays a critical role in intestinal immunity against Salmonella typhimurium infection. *Immunology* 2000. 99(3): 464-72.

84. Darwin, K.H. and V.L. Miller. Molecular basis of the interaction of Salmonella with the intestinal mucosa. *Clin Microbiol Rev* 1999.12(3): 405-28. .

85. Everest, P., *et al.* Evaluation of Salmonella typhimurium mutants in a model of experimental gastroenteritis. *Infect Immun* 1999.67(6): 2815-21.

86. Van den Broeck, W., *et al.* The F4 fnnbrial antigen of Escherichia coli and its receptors. *Vet Microbiol2000.* 71(3-4): 223-44.

87. Heczko, U., A. Abe, and B.B. Finlay. In vivo interactions of rabbit enteropathogenic Escherichia coli 0103 . with its host: an electron microscopic and histopathologic study. *Microbes Infect* 2000. 2(1): 5-16.

88. La Ragione, R.M., W.A. Cooley, and M.J. Woodward. The role offunbriae and flagella in the adherence of avian strains of Escherichia coli O78:K80 to tissue culture cells and tracheal and gut explants. *J Med*

Microbiol 2000. 49(4): 327-38.

89. Martindale, J., *et al.* Genetic analysis of Escherichia coli K1 gastrointestinal colonization. *Mol Microbiol* 2000.37(6): 1293-1305.

90. Phillips, A.D., *et al.* Enterohaemorrhagic Escherichia coli O157:H7 target Peyer's patches in humans and cause attaching/effacing lesions in both human and bovine intestine. *Gut* 2000. 47(3): 377-81.

91. Sun, R., *et al.* Inhibition of adhesion of Escherichia coli k88ac fimbria to its receptor, intestinal mucin-type glycoproteins, by a monoclonal antibody directed against a variable domain of the fimbria. *Infect Immun* 2000.68(6): 3509-15.

92. Jones, N.L., *et al.* Escherichia coli Shiga toxins induce apoptosis in epithelial cells that is regulated by the Bcl-2 family. *Am J Physiol Gastrointest Liver Physiol 2000.* 278(5): G811-9.

93. Baniett Foster, D., *et al.* Enterohemorrhagic Escherichia coli induces apoptosis which augments bacterial binding and phosphatidylethanolamine exposure on the plasma membrane outer leaflet *Infect Immun* 2000. 68(6): 3108-15.

94. Al-Majali, A.M., *et al.* Characterization of the interaction of Escherichia coli heat-stable enterotoxin (STa) with its putative receptor on the intestinal tract of newborn calves. *FEMS Immunol Med Microbiol 2000.* 28(2): 97-104.

95. de Bernard, M., *et al.* The VacA toxin of Helicobacter pylori identifies a new intermediate filament--interacting protein. *Embo J* 2000. 19(1): 48-56.

96. Wessler, S., *et al.* Helicobacter pylori activates the histidine decarboxylase promoter through a mitogenactivated protein kinase pathway independent of pathogenicity island-encoded virulence factors. *J Bioi Chem* 2000.275(5): 3629-36.

97. Rasko, D.A., *et al.* Cloning and characterization of the alpha(1,3/4) fucosyltransferase of Helicobacter pylori. *J Bioi Chem* 2000. 275(7): 4988-94.

98. Donahue, J.P., *et al.* Analysis of iceA 1 transcription in Helicobacter pylori. *Helicobacter* 2000. 5(1): 1-12.

99. Bereswill, S., *et al.* Identification and molecular analysis of superoxide dismutase isoforms in Helicobacter pylori. *FEMS Microbiol Lett* 2000. 183(2): 241-5.

100. Asahi, M., *et al.* Helicobacter pylori CagA protein can be tyrosine phosphorylated in gastric epithelial cells [see comments]. *J Exp Med* 2000. 191(4): 593-602.

101. Logan, S.M., *et al.* Functional genomics of Helicobacter pylori: identification of a beta-1,4 galactosyltransferase and generation of mutants with altered lipopolysaccharide. *Mol Microbiol 2000.* 35(5): 1156-67.

102. Morl, N., *et al.* Activation of intercellular adhesion molecule 1 expression by Helicobacter pylori is regulated by NF-kappaB in gastric epithelial cancer cells. *Infect Immun* 2000.68(4): 1806-14.

103. Beier, D. and R. Frank. Molecular characterization of two-component systems of Helicobacter pylori. *J Bacteriol 2000.* 182(8): 2068-76.

104. Faller, G. and T. Kirchner. Role of anti gastric autoantibodies in chronic. Helicobacter pylori infection. *Microsc Res Tech* 2000. 48(6): 321-6.

105. Morgner, A., *et al.* Gastric MALT lymphoma and its relationship to Helicobacter pylori infection: management and pathogenesis of the disease. *Microsc Res Tech* 2000. 48(6): 349-56.

106. Mittl, P.R., *et al.* The cysteine-rich protein A from Helicobacter pylori is a beta-lactamase. J *Bioi Chem* 2000.275(23): 17693-9.

107. O'Rourke, E.J., *et al.* A novel 3-methyladenine DNA glycosylase from helicobacter pylori defmes a new class within the endonuclease ill family of base excision repair glycosylases. J *Bioi Chem* 2000.

275(26): 20077-83.

108. Kuniyasu, H., *et al.* Helicobacter pylori infection and carcinogenesis of the stomach. *Langenbecks Arch Surg* 2000.385(2): 69-74.

109. Byrd, J.C., *et al.* Inhibition of gastric mucin synthesis by Helicobacter pylori. *Gastroenterology* 2000. 118(6): 1072-9.

110. Beil, W., *et al.* Role of vacA and cagA in Helicobacter pylori inhibition of mucin synthesis in gastric mucous cells. J *Clin Microbiol2000.* 38(6): 2215-8.

111. AIm, R.A., *et al.* Comparative genomics of Helicobacter pylori: analysis of the outer membrane protein families. *Infect Immun* 2000.68(7): 4155-68.

112. Maeda, S., *et al.* H. pylori activates NF-kappaB through a signaling pathway involving IkappaB kinases, NFkappaB-inducing kinase, TRAF2, and TRAF6 in gastric cancer cells. *Gastroenterology* 2000. 119(1): 97108.

113. Endo, T., *et al.* Cloning and expression of beta1,4-galactosyltransferase gene from Helicobacter pylori. *Glycobiology* 2000. 10(8): 809-13.

114. Ebert, M.P., *et al.* Molecular alterations in gastric cancer: the role of Helicobacter pylori. *Eur* J *Gastroenterol HepatoZ2000.* 12(7): 795-8.

115. Monstein, H.J., *et al.* Profiling of bacterial flora in gastric biopsies from patients with Helicobacter pylori-associated gastritis and histologically normal control individuals by temperature gradient gel electropboresis and 16S rDNA sequence analysis. J *Med Microbiol 2000.* 49(9): 817-22.

116. O'Toole, P.W., M.C. Lane, and S. Porwollik. Helicobacter pylori motility. *Microbes Infect* 2000. 2(10): 1207-14.

117. Enroth, H., *et al.* Helicobacter pylori strain types and risk of gastric cancer: a case-control study. *Cancer Epidemiol Biomarkers Prev* 2000. 9(9): 981-5.

118. Solaas, K., *et al.* Subcellular organization of bile acid amidation in human liver: a key issue inregulating the biosynthesis of bile salts. *J Lipid Res* 2000. 41(7): 1154-62.

119. Sodeman, T., *et al.* Bile salts mediate hepatocyte apoptosis by increasing cell surface trafficking ofFas. *Am* J *Physiol Gastrointest Liver Physiol2000.* 278(6): G992-9.

120. Hirohashi, T., *et al.* A TP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3). J *Bioi Chem* 2000. 275(4): 2905-10.

121. Narain, P.K., E.J. DeMaria, and D.M. Heuman. Cholesterol enhances membrane-damaging properties of model bile by increasing the intervesicular-intermixed micellar concentration of hydropbobic bile salts. J *Surg Res* 1999. 84(1): 112-9.

122. Nishioka, T., *et al.* Partial replacement of bile salts causes marked changes of cholesterol crystallization in supersaturated model bile systems. *Biochem* J 1999. 340(Pt 2): 445-51.

123. Stiehl, A., C. Benz, and P. Sauer. Mechanism of hepatoprotective action of bile salts in liver disease. *Gastroenterol Clin North Am* 1999.28(1): 195-209, viii.

124. Nakajima, T., *et al.* Bile acids increase intracellular Ca(2+) concentration and nitric oxide production in vascular endothelial cells. *Br* J *Pharmacol 2000.* 130(7): 1457-67.

125. Agellon, L.B. and E.C. Torchia. Intracellular transport of bile acids. *Biochim Biophys Acta* 2000. 1486(1): 198-209.

126. Reyes, H. and J. Sjovall. Bile acids and progesterone metabolites in intrahepatic cholestasis of pregnancy. *Ann Med* 2000. 32(2): 94-106. .

127. Walters, J.R. Bile acids are physiological ligands for a nuclear receptor. *Gut* 2000. 46(3): 308-9.

128. Ung, K.A., *et al.* Role of bile acids and bile acid binding agents in patients with collagenous colitis. *Gut* 2000. 46(2): 170-5.

129. Orso, E., *et al.* Transport of lipids from golgi to plasma membrane is defective in tangier disease patients and Abc1-deficient mice. *Nat Genet* 2000.24(2): 192-6.

130. Roy, S., *et al.* Dominant-negative caveolin inhibits H-Ras function by disrupting cholesterol-rich plasma membrane domains [see comments]. *Not Cell Biol 1999.* 1(2): 98-105.

131. Roper, K., D. Corbeil, and W.B. Huttner. Retention of prominin in microvilli reveals distinct cholesterol based lipid micro-domains in the apical plasma membrane. *Nat Cell Bioi 2000.* 2(9): 582-592.

132. Zager, RA. Plasma membrane cholesterol: a critical determinant of cellular energetics and tubular resistance to attack. *Kidney Int* 2000.58(1): 193-205.

133. Pralle, A., *et al.* Sphingolipid-cholesterol rafts diffuse as small entities in the plasma membrane of mammalian cells. J *Cell Biol 2000.* 148(5): 997-1008.

134. Verkade, P., *et al.* Induction of caveolae in the apical plasma membrane of Madin-Darby canine kidney cells. J *Cell Bioi* 2000. 148(4): 727-39.

135. Moffett, S., D.A. Brown, and M.E. Linder. Lipid-dependent targeting of G proteins into rafts. J *Bioi* Chem 2000.275(3):2191-8. .

136. Heino, S., *et al.* Dissecting the role of the golgi complex and lipid rafts in biosynthetic transport of cholesterol to the cell surface. *Proc Natl* A cad *Sci* USA 2000. 97(15): 8375-80.

137. Wang, T.Y., R. Leventis, and *J.R* Silvius. Fluorescence-based evaluation of the partitioning of lipids and lipidated peptides into liquid-ordered lipid microdomains: a model for molecular partitioning into “lipid rafts” *Biophys* J2000. 79(2): 919-33.

138. Arduino, C. and E. Gaia. Genetics of chronic pancreatitis. *Biomed Pharmacother* 2000. 54(7): 394-9.

139. Chen, J.M. and C. Ferec. Molecular basis of hereditary pancreatitis. Eur J *Hum Genet* 2000. 8(7): 473-9.

140. Whitcomb, D.C. Genetic predispositions to acute and chronic pancreatitis. *Med Clin North* Am 2000. 84(3): 531-47, vii.

141. Kleeff, *J., et al.* Chronic pancreatitis: pathogenesis and molecular aspects. *Ann Ital Chir* 2000. 71(1): 3-10.

142. Teich, N., A. Hoffmeister, and V. Keirn. Nomenclature *of* trypsinogen mutations in hereditary pancreatitis. *Hum Mutat* 2000. 15(2): 197-8.

143. Smithies, A.M., *et al.* Investigation of the interleukin 1 gene cluster and its association with acute pancreatitis. *Pancreas* 2000. 20(3): 234-40.

144. O'Reilly, D .A., *et al.* Association of tumour necrosis factor microsatellite haplotypes with chronic pancreatitis. *Br* J Surg *2000.87(3):* 362-73.

145. Mickle, J.E. and G.R Cutting. Genotype-phenotype relationships in cystic fibrosis. Med C/in *North* Am 2000. 84(3): 597-607.

146. Linsdell, P., A. Evagelidis, and J.W. Hanrahan. Molecular determinants of anion selectivity in the cystic fibrosis transmembrane conductance regulator chloride channel pore. *Biophys* J *2000.* 78(6): 2973-82.

147. Zielenski, *J.* Genotype and phenotype in cystic fibrosis. *Respiration* 2000. 67(2): 117-33.

148. Mickle, *J* .E., *et al.* Effects of cystic fibrosis and congenital bilateral absence of the vas deferens-associated mutations on cystic fibrosis transmembrane conductance regulator-mediated regulation of separate channels. Am J *Hum Genet* 2000. 66(5): 1485-95.

149. Chen, E.Y., M.C. Bartlett, and D.M. Clarke. Cystic fibrosis transmembrane conductance regulator has an altered structure when its maturation is inhibited. *Biochemistry* 2000. 39(13): 3797-803.

150. Skach, W.R Defects in processing and trafficking of the cystic fibrosis transmembrane conductance regulator. *Kidney Int 2000.* 57(3): 825-31.

151. Lu, N.T. and P.L. Pedersen. Cystic fibrosis transmembrane conductance regulator: the purified NBF1+R protein interacts with the purified NBF2 domain to form a stable NBF1 +R/NBF2 complex while inducing a conformational change transmitted to the C-terminal region [published erratum appears in Arch Biochem Biophys 2000 May 1;377(1):213]. Arch *Biochem Biophys* 2000. 375(1): 7-20.

152. Weixel, K.M. and N.A. Bradbury. The carboxyl terminus of the cystic fibrosis transmembrane conductance regulator binds to AP-2 clathrin adaptors. J *Bioi* Chem 2000. 275(5): 3655-60.

153. Hershkovits, B.S., *J.* Dagan, and S. Freier. Increased spontaneous chromosomal breakage in Shwachman syndrome. J *Pediatr Gastroenterol Nutr* 1999. 28(4): 449-50.

154. Goobie, S., *et al.* Exclusion of linkage of Shwachman-Diamond syndrome to chromosome regions 6q and. 12q implicated by a de novo translocation. Am J Med *Genet* 1999: 85(2): 171-4.

155. Ikegawa, S., *et al.* Cloning of translocation breakpoints associated with Shwachman syndrome and identification of a candidate gene. *Clin Genet* 1999. 55(6): 466-72.

156. Dror, Y. and M.H. Freedman. Shwachman-Diamond syndrome: An inherited preleukemic bone marrow failure disorder with aberrant hematopoietic progenitors and faulty marrow microenvironment *Blood* 1999. 94(9): 3048-54.

157. Klupp, N., *et al.* Emergence of an unusual bone marrow precursor B-cell population in fatal Shwachman Diamond syndrome. Arch *Pathol* Lab Med 2000. 124(9): 1379-81.

158. Bouchard, G., *et al.* High-resolution maps of the murine Chromosome 2 region containing the cholesterol gallstone locus, Lith1. *Mamm Genome* 1999. 10(11): 1070-4.

159. Lammert, F., *et al.* Phenotypic characterization of Lith genes that determine susceptibility to cholesterol cholelithiasis in inbred mice: integrated activities of hepatic lipid regulatory enzymes. *J Lipid Res* 1999. 40(11): 2080-90. .

160. Han, T., *et al.* Apolipoprotein B-100 gene Xba 1 polymorphism and cholesterol gallstone disease. *Clin Genet* 2000.57(4): 304-8.

161. Rubin, M., R. Pakula, and F.M. Konikoff. Microstructural analysis of bile: relevance to cholesterol gallstone pathogenesis. *Histol Histopathol 2000.* 15(3): 761-70.

162. Hattori, Y., *et al.* Role of phospholipase A2 in cholesterol gallstone formation is associated with biliary phospholipid species selection at the site of hepatic excretion: indirect evidence. *Dig Dis Sci* 2000. 45(7):1413-21.

163. Hrbasova, M., *et a1.* Artificial lipid-protein complexes accelerate cholesterol crystallisation in model bile. *Int J Bioehem Cell Bioi* 2000. 32(6): 609-19.

164. Amigo, L., *et al.* Impaired biliary cholesterol secretion and decreased gallstone formation in apolipoprotein E-deficient mice fed a high-cholesterol diet *Gastroenterology* 2000. 118(4): 772-9.

165. Xiao, Z.L., *et al.* Defect of receptor-G protein coupling in human gallbladder with cholesterol stones. *Am J Physiol Gastrointest Liver Physiol2000.* 278(2): G251-8.

166. Wang, D.Q., *et al.* Cholic acid aids absorption, biliary secretion, and phase transitions of cholesterol in murine cholelithogenesis. *Am J Physiol1999.* 276(3 Pt 1): G751-60.

167. Wang, D. Q., *et al.* No pathophysiologic relationship of soluble biliary proteins to cholesterol crystallization in human bile. *J Lipid Res* 1999.40(3): 415-25.

168. Tang, C., *et al.* Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-n inhibitor. *J Pharmacol Exp Ther* 2000. 293(2): 453-9.

169. Raza, H., *et al.* Cloning, characterisation and bacterial expression of full length cDNA for the mouse liver microsomal glutathione S-transferase. *Oneol Rep* 2000. 7(3): 645-9.

170. Muratori, L., *et al.* Liverlkidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane [see comments]. *Gut* 2000.46(4): 553-61.

171. Matsunaga, T., *et al.* Characterization of microsomal alcohol oxygenase catalyzing the oxidation of 7 hydroxy-delta 8-tetrahydrocannabinol to 7-oxo-delta 8-tetrahydrocannabinol in rat liver. *Bioi Pharm Bull* 2000. 23(1): 43-6.

172. Jolly, C.A., D.C. Wilton, and F. Schroeder. Microsomal fatty acyl-CoA transacylation and hydrolysis: fatty acyl-CoA species dependent modulation by liver fatty acyl-CoA binding proteins. *Bioehim Biophys Acta* 2000. 1483(1): 185-97. .

173. Teyssier, C., *et al.* Metabolism of diallyl disulfide by human liver microsomal cytochromes P-450 and flavin containing monooxygenases. *Drug Metab Dispos* 1999.27(7): 835-41.

174. Raabe, M., *et al.* Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice. *J Clin Invest* 1999. 103(9): 1287-98.

175. Oleksiak, M.F., *et al.* Identification, functional characterization, and regulation of a new cytochrome P450 subfamily, the CYP2Ns. *J Bioi Chem* 2000. 275(4): 2312-21.

176. Okamoto, T. and S. Okabe. Minimal effect of cytokine-independent hepatitis induced by anti-Fas antibodies on hepatic cytochrome P450 gene expression in mice. *Int J Mol Med* 2000. 6(4): 459-62.

177. O'Leary, K.A. and C.B. Kasper. Molecular basis for cell-specific regulation of the NADPH-cytochrome P450 oxidoreductase gene. *Arch Biochem Biophys* 2000. 379(1): 97-108.

178. Okamoto, T. Suppression of cytochrome P450 gene expression in the livers of mice with concanavalin A-induced hepatitis. *Eur J Pharmacol 2000.* 394(1): 157-61.

179. Marc, N., *et al.* Regulation of phenobarbital induction of the cytochrome P450 *2b9/10* genes in primary mouse hepatocyte culture. Involvement of calcium- and cAMP-dependent pathways. *Eur J Biochem* 2000. 267(4): 963-70.

180. Larrey, D. Drug-induced liver diseases. *J Hepatol 2000.* 32(1): 77-88.

181. Aithal, P.G. and C.P. Day. The natural history of histologically proved drug induced liver disease. *Gut* 1999. 44(5): 731-5.

182. Crouch. M.A. and D.F. Brophy. Nonsteroidal antiinflammatory drug-induced hepatitis. *Ann Pharmaeother* 1998. 32(3): 386.

183. Okamoto, T., K. Yamamura, and O. Hino. Expression of the inducible form of the nitric oxide synthase gene in the livers of mice with chronic hepatitis. *Int J Mol Med* 2000. 6(3): 315-7.

184. Nutt, A.K., *et al.* Liver biopsy in the evaluation of patients with chronic hepatitis C who have repeatedly normal or near-normal serum alanine aminotransferase levels [see comments]. *Am J Med* 2000. 109(1): 62-4.

185. Marra, F., *et al.* Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. *Gastroenterology* 2000. 119(2): 466-78.

186. Umemura, T., *et al.* Analysis ofT cell repertoire in the liver of patients with chronic hepatitis C. *Clin Exp Immunol 2000.* 121(1): 120-6.

187. Van, J., *et al.* Expression of vascular endothelial growth factor in liver tissues of hepatitis B. *Chung Hua*

Kan Tsang Ping Tsa Chih 2000. 8(3): 150-2.

188. Soguero, C., *et al.* Assessment of genotype and molecular evolution of hepatitis C virus in formalin-fixed paraffm-embedded liver tissue trom patients with chronic hepatitis C virus infection. *Lab Invest* 2000. 80(6): 851-6.

189. Thomas, R.M., *et al.* Alphal-antichymotrypsin globules within hepatocytes in patients with chronic hepatitis C and cirrhosis. *Hum Pathol 2000.* 31(5): 575-7.

190. Bertolino, P., G. Klimpel, and S.M. Lemon. Hepatic inflammation and immunity: a summary of a conference on the function of the immune system within the liver. *Hepatology* 2000. 31(6): 1374-8.

191. Eckels, D.D., *et al.* Immunobiology of hepatitis C virus (HCV) infection: the role of CD4 T cells in HCV infection. *Immuno/ Rev* 2000. 174: 90-7.

192. Rockey, D.C. Hepatic fibrogenesis and hepatitis C. *Semi Gastrointest Dis* 2000. 11(2): 69-83.

193. Wies, I., *et al.* Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis [see comments]. *Lancet* 2000.355(9214): 1510-5.

194. Takeda, K., *et al.* Critical contribution of liver natural killer T cells to a murine model of hepatitis. *Proc Natl Acad Sci USA* 2000. 97(10): 5498-503.

195. Pinto, M.A., *et al.* Inducible nitric oxide synthase (iNOS) expression in liver and splenic T lymphocyte rise are associated with liver histological damage during experimental hepatitis A virus (HAV) infection in Callithrixjacchus. *Exp Toxicol Patol 2000.* 52(1): 3-10.

196. Aurisicchio, L., *et al.* Liver-specific alpha 2 interferon gene expression results in protection from induced hepatitis. *J Virol 2000.* 74(10): 4816-23.

197. Nasir, A., H.S. Arora, and H.E. Kaiser. Apoptosis and pathogenesis of viral hepatitis C--an update. *In Vivo* 2000. 14(1): 297-300.

198. Ohashi, K., *et al.* Sustained survival of human hepatocytes in mice: A model for in vivo ilifection with human hepatitis B and hepatitis delta viruses. *Not Med* 2000.6(3): 327-31.

199. Ramalho, F., *et al.* Correlation of genotypes and route of transmission with histologic activity and disease stage in chronic hepatitis C. *Dig Dis Sci* 2000. 45(1): 182-7.

200. Ishak, K.G. Pathologic features of chronic hepatitis. A review and update. *Am J Clin Pathol 2000.* 113(1): 40-55.

201. Ramakrishna, B., *et al.* Familial intrahepatic cholestatic cirrhosis with positive antimitochondrial antibody: familial primary biliary cirrhosis. *J Clin Gastroentero/2000.* 30(3): 255-8.

202. Clemente, M.G. and S. De Virgiliis. Autoantigen characterization in liver/kidney microsome positive hepatitis. *Dig Liver Dis* 2000. 32(1): 39-45.

203. Duclos- Vallee, J.C., *et al.* Autoantibodies associated with acute rejection after liver transplantation for type-2 autoimmune hepatitis. *J Hepatol 2000.* 33(1): 163-6.

204. Czaja, A.J., *et al.* Autoimmune cholangitis within the spectrum of autoimmune liver disease. *Repatology* 2000. 31(6): 1231-8.

205. Czaja, A.J. and P.T. Donaldson. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. *Immunol Rev* 2000. 174: 250-9.

206. Kanzler, S., *et al.* Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. *J Hepatol 1999.* 31(4): 635-40.

207. Mangia, A., *et al.* Anticardiolipin antibodies in patients with liver disease. *Am J Gastroenterol 1999.* 94(10): 2983-7.

208. Mackay, I.R., J.M. Davies, and M.J. Rowley. Towards the pathogenesis of autoimmune liver disease. *J*

Autoimmun 1999. 13(1): 163-9.

209. Ludwig, J. The pathology of primary biliary cirrhosis and autoimmune cholangitis. *Baillieres Best Pract Res Clin Gastroenterol 2000.* 14(4): 601-13.

210. Gershwin, M.E., *et al.* Primary biliary cirrhosis: an orchestrated immune response against epithelial cells. *Immunol Rev* 2000. 174: 210-25.

211. Lieber, C.S. Alcohol and the liver: metabolism of alcohol and its role in hepatic and extrahepatic diseases. Mt *Sinai J* Med 2000. 67(1): 84-94.

212. Kono, H., *et al.* Gender differences in early alcohol-induced liver injury: role of CD14, NF-kappaB, and TNF-alpha. *Am J Physiol Gastrointest* Liver *Physiol* 2000. 278(4): 0652-61.

213. Bautista, A.P. hnpact of alcohol on the ability ofKupffer cells to produce chemokines and its role in alcoholic liver disease. *J Gastroenterol Hepatol* 2000. 15(4): 349-56.

214. Enomoto, N., et *al.* Kupffer cell-derived prostaglandin E(2) is involved in alcohol-induced fat accwnulation in rat liver. Am *J Physiol Gastrointest Liver Physiol* 2000. 279(1): 0100-6.

215. Keshavarzian, A., et *al.* Leaky gut in alcoholic cirrhosis: a possible mechanism *for* alcohol-induced liver damage. Am *J Gastroenterol* 1999. 94(1): 200-7.

216. McPhaul LW, Wang *J,* Hol EM et al. Molecular misreading of the ubiquitin B gene and hepatic Mallory body formation. Gastroenterology 2002; 122:1878-1885.

217. Enomoto, N., et *al.* Development ofa new, simple rat model of early alcohol-induced liver injury based on sensitization of Kupffer cells. *Hepatology* 1999.29(6): 1680-9.

218. Ikejima K, Takei Y, Honda H et al. Leptinreceptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellualr matrix in the rat. *Gastroenterology* 2002; 122:1399-1410.

219. Lin, S.C., *et al.* The influence of propolis ethanol extract on liver microsomal enzymes and glutathione after chronic alcohol administration. Am *J* Chin Med 1999. 27(1): 83-93.

220. Lin HZ, Yang SQ, Chckaree C, *et al*. Metformin reverses fatty liver disease in obese, leptin deficient mice. *Nat Med* 2000; 6:998-1003

221. Pinzani, M. and P. Gentilini. Biology of hepatic stellate cells and their possible relevance in the pathogenesis of portal hypertension in cirrhosis. Semin *Liver* Dis 1999. 19(4): 397-410.

222. Vasiliou, V., *et al.* Involvement of p65 in the regulation of NF-kappaB in rat hepatic stellate cells during cirrhosis. *Biochem Biophys* Res *Commun* 2000. 273(2): 546-50.

223. Levy, M.T., *et al.* Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. *Hepatology* 1999.29(6): 1768-78.

224. Levine, D., et *al*. Expression of the integrin alpha8betalduring pulmonary and hepatic fibrosis. Am *J Pathol* 2000. 156(6): 1927-35.

225. Okazaki, I., *et al*. Molecular mechanism of the reversibility of hepatic fibrosis: with special reference to the role of matrix metalloproteinases. *J Gastroenterol Hepatol2000.* 15 Suppl: D26-32.

226. Brenner, D.A., *et al.* New aspects of hepatic fibrosis. *J Hepato12000.* 32(1): 32-8.

227. Friedman, S.L. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. *J Bioi* Chem 2000. 275(4): 2247-50.

228. McCrudden, R. and J.P. Iredale. Liver fibrosis, the hepatic stellate cell and tissue inhibitors of metalloproteinases. *Histol Histopathol* 2000. 15(4): 1159-68.

229. Ozaki, I., *et al.* Ribozyme-mediated specific gene replacement of the alpha1-antitrypsin gene in human

hepatoma cells. *J Hepatol* 1999. 31(1): 53-60. .

230. Gaillard, M.C., R Mahadeva, and D.A. Lomas. Identification of DNA polymorphisms associated with the V type alphal-antitrypsin gene. *Biochim Biophys* Acta 1999. 1444(2): 166-70.

231. Zhang, G., Y.K. Song, and D. Liu. Long-term expression of human alphal-antitrypsin gene in mouse liver achieved by intravenous administration of plasmid DNA using a hydrodynamics-based procedure. Gene *Ther* 2000. 7(15): 1344-9.

232. Volpert, D., J.P. Molleston, and D.H. Perlmutter. Alphal-antjtrypsin deficiency-associated liver disease progresses slowly in some children. *J Pediatr Gastroenterol Nutr* 2000. 31(3): 258-63.

233. Parmar, J.S. and D.A. Lomas. Alpha-1-antitrypsin deficiency, the serpinopathies and conformational disease. *J R Coll Physicians Lond* 2000. 34(3):295-300.

234. Lomas, D.A. Loop-sheet polymerization: the mechanism of alpha1-antitrypsin deficiency. *Respir Med* 2000. 94 Suppl C:S3-6.

235. Rigotti, A. and D.E. Cohen. The Tangier disease gene encodes yet another pathophysiologically relevant atp-binding cassette protein. *Hepatology* 2000. 11(2): 117-22.

236. Hayden, M.R., et *al.* Cholesterol efflux regulatory protein, Tangier disease and familial high-density lipoprotein deficiency. Curr *Opin Lipidol2000.* 11(2): 117-22.

237. Ordovas, J.M. ABC1: the gene for Tangier disease and beyond. *Nutr Rev* 2000. 58(3 Pt 1): 76-9.

238. Schuler-Luttmann, S., *et al.* Cholesterol efflux from normal and Tangier disease fibroblasts into normal, high-density lipoprotein-deficient, and apolipoprotein E-deficient plasmas. *Metabolism* 2000. 49(6): 770-7.

239. Gerin, 1., *et al.* Structure of the gene mutated in glycogen storage disease type lb. Gene 1999. 227(2): 189-95.

240. Hou, D.C., *et al.* Glycogen storage disease type Ib: structural and mutational analysis of the microsomal glucose-6-phosphate transporter gene. Am J Med *Genet* 1999.86(3): 253-7.

241. Galli, L., *et al.* Mutations in the glucose-6-phosphate transporter (G6PT) gene in patients with glycogen storage diseases type 1b and 1c. *FEBS LeU* 1999. 459(2): 255-8.

242. LiD, B., *et al.* Type-1c glycogen storage disease is not caused by mutations in the glucose-6-phosphate transporter gene. *Hum Genet* 1999.105(5): 515-7.

243. Chiang, S.C., *et al.* Glucose-6-phosphatase gene mutations in Taiwan Chinese patients with glycogen storage disease type Ia. J *Hum Genet 2000.* 45(4): 197-9.

244. Okubo, M., *et al.* Heterogeneous mutations in the glycogen-debranching enzyme gene are responsible for glycogen storage disease type ma in Japan. *Hum Genet* 2000. 106(1): 108-15.

245. Li, P., A.B. Bellows, and J.N. Thompson. Molecu1arbasis ofiduronate-2-sulphatase gene mutations in patients with mucopolysaccharidosis type n (Hunter syndrome). J Med *Genet* 1999. 36(1): 21-7.

246. Bunge, S.; *et al.* Mucopolysaccharidosis type IIIB (Sanfilippo B): identification of 18 novel alpha-N acetylglucosaminidase gene mutations. J Med *Genet* 1999. 36(1): 28-31.

247. Hartung, S.D., *et al.* Enzymatic correction and cross-correction of mucopolysaccharidosis type I fibroblasts by adeno-associated virus-mediated transduction of the alpha-L-iduronidase gene. *Hum Gene* Ther 1999.10(13): 2163-72.

248. Kosuga, M., *et al.* Adenovirus-mediated gene therapy *for* mucopolysaccharidosis VII: involvement of crosscorrection in wide-spread distribution of the gene products and long-term effects ofCfLA-4Ig coexpression. *Mol* Ther 2000.1(5 Pt 1): 406-13.

249. Sukegawa, K., *et al.* Biochemical and structural analysis of missense mutations in N-acetylgalactosamine-6 sulfate sulfatase causing mucopolysaccharidosis IV A phenotypes. *Hum Mol Genet* 2000. 9(9): 1283-90.

250. Bosch, A., *et al.* Reversal of pathology in the entire brain of mucopolysaccharidosis type in mice after lentivirus-mediated gene transfer. *Hum Gene* Ther 2000. 11(8): 1139-50.

251. Vervoort, R, *et al.* Low beta-glucuronidase enzyme activity and mutations in the human beta-glucuronidase gene in mild mucopolysaccharidosis type vn, pseudodeficiency and a heterozygote. *Hum Genet* 1998. 102(1): 69-78.

252. Beesley, C.E., *et al.* Identification *of* 12 novel mutations in the alpha-N-acetylglucosaminidase gene in 14 patients with Sanfilippo syndiome type B (mucopolysaccbaridosis type IIIB). J Med *Genet* 1998. 35(11): 910-4.

253. Karsten, S.L., *et al.* Identification of 9 novel IDS gene mutations in 19 unrelated Hunter syndrome (mucopolysaccharidosis Type ll) patients. Mutations in brief no. 202. Online. *Hum Mutat* 1998.12(6): 433.

254. Winchester, B., A. Vellodi, and E. Young. The molecular basis of lysosomal storage diseases and their treatment *Biochem* Soc *Trans* 2000. 28(2): *150-4.*

255. Isaac, E.L., *et al.* Regulation of the lysosome-associated membrane protein in a sucrose model *of* lysosomal storage. Exp *Cell* Res 2000. 254(2): 204-9.

256. Eto, Y. and T. Ohashi. Gene therapy/cell therapy for lysosomal storage disease. J *Inherit Metab* Dis 2000. 23(3): 293-8.

257. Schuchman, E.H. Hematopoietic stem cell gene therapy *for* Niemann-Pick disease and other lysosomal storage diseases. *ChemPhys Lipids* 1999.102(1-2): 179-88.

258. Anderson, RA., G.M. Bryson, and *J.S.* Parks. Lysosomal acid lipase mutations that determine phenotype in Wolman and cholesterol ester storage disease. *Mol Genet Metab* 1999. 68(3): 333-45.

259. vom Dahl, S., *et al.* Hepatosplenomegalic lipidosis: what unless Gaucher? Adult cholesteryl ester storage disease (CESD) with anemia, mesenteric lipodystrophy, increased plasma chitotriosidase activity and a homozygous lysosomal acid lipase -1 exon 8 splice junction mutation. J *Hepato* 1999. 31(4): 741-6.

260. Ziegler, *RJ., et al.* Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus mediated gene transfer. *Hum* Gene Ther 1999.10(10): 1667-82. .

261. Sleat, D.E., *et al.* Mutational analysis of the defective protease in classic late-infantile neuronal ceroid lipofuscinosis, a neurodegenerative lysosomal storage disorder. Am J *Hum Genet* 1999. 64(6): 1511-23.

262. Havelaar, A.C., *et al.* Transport of organic anions by the lysosomal sialic acid transporter: a functional approach towards the gene *for* sialic acid storage disease. FEBS *Leu* 1999. 446(1): 65-8.